JPRN-jRCT2031230311招募中1 期
CCH2212, An investigator initiated Phase I trial to determine the recommended dose of diagnostic radioactive drug 64Cu-NCAB001 in pancreatic cancer patients without clinically distant metastasis - PRIME-64
Hijioka Susumu0 个研究点目标入组 18 人开始时间: 2023年8月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 80age old（—）
入选标准
- •1) Contrast-enhanced CT shows typical imaging findings such as pancreatic mass/dilation of the caudal pancreatic duct with low absorption area, and as a result of diagnostic imaging, it shows strong clinical suspicion of pancreatic cancer due to such as elevation tumor maker (CA19-9). However, the participant has regional lymph node metastasis around the primary tumor and is diagnosed as resectable or resectable borderline pancreatic cancer, is eligible
- •2) Schedluded for cytological or histoligical diagnosis with EUS
- •3) Age at registration is between 18 and 80 years
- •4) Performance Status (ECOG) is 0 or 1
- •5) Not receieved surgical resection, chemotherapy, or radiation therapy (including gamma knife and cyber knife) for pancreatic or gastrointestinal cancer
- •6) Having all laboratory tests performed within 14 days before registration and the values are within the following range. Howerber, participants should not recieve administration of blood transfusion within 14 days before the blood collection.
- •(1) White blood cells count >= 3,500 /mm3
- •(2) Hemoglobin >=9.0 g/dL
- •(3) Platelet count >=100,000 /mm3
- •(4) Albmine >=3.0 g/dL
- •(5) Aspartate aminotransferase (AST) <=100 U/L and Alanine aminotransferase (ALT) <=100 U/L ( <=150
- •U/L with bile duct drainage)
- •(6) Total bilirubin <=2.0 mg/dL (<=3.0 mg/dL with bile duct drainage)
- •(7) Serum creatinine <=1.2 mg/dL
- •(8) PT-INR <=1.5
- •7) Consent to at least 4 months of restriction of breastfeeding for lactating participant, and consent to
- •at least 4 months of contraception(*) from the start of administration with investigational product
- •for male participant.
- •*Contraceptive method: Dual contraception by any two of the following: condom, oral contraceptive pills, or intrauterine device. However, implanted contraceptive devices, pessaries (including those with sprmicide), cervival caps with spermicides, and contraceptive sponges (including spermicides) are disable because of not approved or certified in Japan.
- •8) Written informed consent
排除标准
- •1) Participants with a strong clinical suspicion of pancreatic cancer but unresectable (with locally advanced or distant metastasis) by contrast-enhanced CT performed within 14 days prior to the date of registration
- •2) Active double primary cancer (but not (1)-(3)): (1) completely resected following cancers: basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, (2) gastrointestinal cancer curatively resected with ESD or EMR, and (3) other cancers with no recurrence for more than 5 years.)
- •3) Participants with infections requiring systemic treatment.
- •4) Previous serious(*) hypersensitive reaction or allergy to CT contraset agent, cetuximab, or component of investigational product
- •5) Participants with complications or history of interstitial pneumonia or pulmonary fibrosis diagnosed by imaging or clinical findings
- •6) Participants with ascites or pleural effusion that exceeds the physiological range
- •7) Participants with uncontrolled diabetes mellitus, serious(*) heart disease, angina pectoris, history of myocardial infarction within 3 months prior to the date of registration, serious(*) hepatic disorder, or serious(*) phychiatric disease
- •8) Female participants who are pregnant or may become pregnant : Non-menopausal female particiapants who have not undergone surgical sterlization (hysterectomy or bilateral oophorectomy). Menopause is defined as her 12 months or longer without menstruation without other medical reasons such as medication.
- •9) Participants who are judged by the investigator or sub-investigator to be unsuitable for the trial due to medical, psychological or other factors
- •*: serious is defined as Grade 2 in the Criteria for Classifying Seriousness of Adverse Drug Ractions (Notification No. 80 of the Safety Division of the Pharmaceutical Affairs Bureau, Ministry of Health and Welfare dated June 29, 1992).
- •https://www.mhlw.go.jp/shingi/2005/10/dl/s1006-4f2.pdf
研究者
相似试验
进行中（未招募）
2 期
Atezolixumab in patients with relapsed/refractory NK/T-cell lymphomaextranodal NK/T-cell lymphoma, nasal type (ENKL)ENKLD054391ENKJPRN-jRCT2031190177Izutsu Koji20
已完成
不适用
An investigator initiated phase II clinical trial of Tamibarotene (AM80G) for chronic graft-versus-host diseaseRecipients refractory or resistant chronic GVHD to therapy with corticosteroidJPRN-UMIN000020363Okayama University Hospital18
已完成
1 期
Phase I investigator initiated clinical trial using a novel WT1 peptide vaccine for patients with metastatic pancreatic cancerpancreatic cancerJPRN-UMIN000029428Wakayama Medical University6
进行中（未招募）
2 期
An investigator-initiated, phase II clinical trial of the peptide-based cancer vaccine targeting WT1, DSP-7888, for colorectal adenomas in familial adenomatous polyposisFAPfamilial adenomatous polyposisJPRN-jRCT2051200082Shichijo Satoki30
进行中（未招募）
1 期
The investigator-initiated clinical trial, booster vaccination against COVID-19 (KD-414)Prevention of COVID-19JPRN-jRCT2031210503Koga Michiko160